Skip to main content
Account

Peer review reports

From: Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand

Original Submission
21 Jun 2024 Submitted Original manuscript
26 Jun 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 2
26 Jun 2024 Submitted Manuscript version 2
27 Jun 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 3
27 Jun 2024 Submitted Manuscript version 3
14 Jul 2024 Reviewed Reviewer Report
19 Jul 2024 Reviewed Reviewer Report - Pornchai O-Charoenrat
28 Jul 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 4
28 Jul 2024 Submitted Manuscript version 4
30 Jul 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 5
30 Jul 2024 Submitted Manuscript version 5
1 Aug 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 6
1 Aug 2024 Submitted Manuscript version 6
2 Aug 2024 Author responded Author comments - Thitiya Dejthevaporn
Resubmission - Version 7
2 Aug 2024 Submitted Manuscript version 7
Publishing
5 Aug 2024 Editorially accepted
16 Aug 2024 Article published 10.1186/s12885-024-12765-x

Learn about peer review

Back to article page

Navigation